Structure Therapeutics reports Q3 results

* Structure Therapeutics press release [https://seekingalpha.com/pr/20297762-structure-therapeutics-reports-third-quarter-2025-financial-results-and-recent-highlights] (GPCR [https://seekingalpha.com/symbol/GPCR]): Q3 net loss for the third quarter of 2025 totaled $65.7 million, with non-cash share-based compensation expense of $7.5 million, compared to $34.0 million for the third quarter of 2024 with non-cash share-based compensation expense of $6.0 million.
* Cash, cash equivalents and short-term investments totaled $799.0 million as of September 30, 2025. The Company expects its current cash, cash equivalents and short-term investments to fund projected operations and key clinical milestones through at least 2027. For aleniglipron, this includes costs related to the ongoing ACCESS and ACCESS II studies, extension studies, the supplementary studies, and Phase 3 readiness activities, but excludes Phase 3 registrational studies.

MORE ON STRUCTURE THERAPEUTICS

* Structure Therapeutics: The Dark Horse In The Oral Obesity GLP-1 Arena [https://seekingalpha.com/article/4827742-structure-therapeutics-dark-horse-in-the-oral-obesity-glp-1-arena]
* Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) [https://seekingalpha.com/article/4821605-structure-therapeutics-inc-gpcr-presents-at-morgan-stanley-23rd-annual-global-healthcare]
* Structure Therapeutics: Key Milestones Dead Ahead [https://seekingalpha.com/article/4814312-structure-therapeutics-key-milestones-dead-ahead]
* Seeking Alpha’s Quant Rating on Structure Therapeutics [https://seekingalpha.com/symbol/GPCR/ratings/quant-ratings]
* Historical earnings data for Structure Therapeutics [https://seekingalpha.com/symbol/GPCR/earnings]